Affinivax’s MAPS Vaccine Technology Reaches Clinic In Under Five Years
Executive Summary
Funded entirely by grants and partnerships to date, Affinivax’s pneumococcal vaccine candidate has begun a Phase I/II study less than five year’s after the biotech’s founding. Firm thinks its technology may eventually apply to immuno-oncology as well.
You may also be interested in...
Keeping Track: FDA Approves First Generic Advair, But Alkermes And Sunovion Land CRLs
The latest drug development news and highlights from our US FDA Performance Tracker.
Pfizer: Time To Face The Lyrica Pain
Pfizer forecast flat US drug prices in 2019 and downplayed large M&A as a way to assuage near-term growth concerns, while investors brace for a challenging period cycling through the loss of Lyrica.
Astellas Builds Vaccine Portfolio With Affinivax Pneumococcal Candidate
Despite one recent setback, Astellas is continuing to expand its vaccines business through a new global deal for Affinivax's lead MAPS pneumococcal product, in a move that builds on earlier research links between the companies.